On Mar. 16, 2020, Aimmune Therapeutics announced that the first patients in the U.S. were being treated with PALFORZIA, [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first approved treatment for peanut allergy.

Following the release of the medication lots by the U.S. Food and Drug Administration (FDA), specialty pharmacies are shipping PALFORZIA initial dosing kits to allergists for in-office administration to their peanut-allergic patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy.